Inhibition of centrosomal protein 164 sensitizes rhabdomyosarcoma cells to radiotherapy

Liu,Jianzhou; Wang,Zhiju; Li,Xiaofeng; Zhang,Xu; Zhang,Chaoji

doi:10.3892/etm.2017.4281

May-2017 Volume 13 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2017 Volume 13 Issue 5

Full Size Image

Article Open Access

Inhibition of centrosomal protein 164 sensitizes rhabdomyosarcoma cells to radiotherapy

Authors:
- Jianzhou Liu
- Zhiju Wang
- Xiaofeng Li
- Xu Zhang
- Chaoji Zhang
View Affiliations / Copyright

Affiliations: Department of Cardiac Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China, Department of Physiology, School of Basic Medicine Science, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China

Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 2311-2315
|
Published online on: March 29, 2017

https://doi.org/10.3892/etm.2017.4281
Expand metrics +

Abstract

Rhabdomyosarcoma is the second most common malignant tumor of the heart in infants and children and cannot often be resected completely. Chemotherapy and radiotherapy have a critical role in relieving symptoms and prolonging survival; therefore, enhancing the sensitivity of rhabdomyosarcoma to radiotherapy is an important area of investigation in order to improve the prognosis of patients. It has been reported that centrosomal protein 164 (CEP164) has a key role in the DNA damage‑activated signaling cascade. CEP164 is often overexpressed in tumors and is associated with poor prognosis in various types of cancer. In the present study, the influence of CEP164 on the radiosensitivity of rhabdomyosarcoma cells was investigated. Results demonstrated that CEP164 is involved in the radiation‑induced cellular response. CEP164 is increased upon radiation and influences the cell cycle, cell viability and cell apoptosis. CEP164 depletion enhanced cellular sensitivity to radiation, promoted cell apoptosis, decreased cell viability and induced gap 2/mitosis arrest of the cell cycle. The present study identified the function of CEP164 in radiation resistance in rhabdomyosarcoma, providing a potential therapeutic target for rhabdomyosarcoma treatment by disrupting CEP164.

View Figures

View References

1	Yilmaz M, Kehlibar T, Arslan IY, Yilmaz HY, Tarhan IA and Ozler A: A case of primary cardiac rhabdomyosarcoma with surgical removal and mitral valve repair. Heart Surg Forum. 16:E164–E166. 2013. View Article : Google Scholar : PubMed/NCBI
2	Abraham R: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177–2196. 2001. View Article : Google Scholar : PubMed/NCBI
3	Čajánek L and Nigg EA: Cep164 triggers ciliogenesis by recruiting Tau tubulin kinase 2 to the mother centriole. Proc Natl Acad Sci USA. 111:E2841–E2850. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, et al: Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell. 150:533–548. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chen K: Rhabdomyosarcoma in an adult presenting with nodal metastasis: A pitfall in fine-needle aspiration cytology of lymph nodes. Diagn Cytopathol. 32:303–306. 2005. View Article : Google Scholar : PubMed/NCBI
6	Graser S, Stierhof YD, Lavoie SB, Gassner OS, Lamla S, Le Clech M and Nigg EA: Cep164, a novel centriole appendage protein required for primary cilium formation. J Cell Biol. 179:321–330. 2007. View Article : Google Scholar : PubMed/NCBI
7	Guo L, Wang ZY, Zou YB and Bi LR: Primary cardiac embryonal rhabdomyosarcoma: Report of a case. Zhonghua Bing Li Xue Za Zhi. 42:621–622. 2013.(In Chinese). PubMed/NCBI
8	Ma J, Sun JP, Chen M, Zhang L, Xu N, Wang J, Pui-wai Lee A and Yu CM: Left atrial rhabdomyosarcoma. Circulation. 129:e503–505. 2014. View Article : Google Scholar : PubMed/NCBI
9	Merlino G and Helman LJ: Rhabdomyosarcoma-working out the pathways. Oncogene. 18:5340–5348. 1999. View Article : Google Scholar : PubMed/NCBI
10	Pan YR and Lee EY: UV-dependent interaction between Cep164 and XPA mediates localization of Cep164 at sites of DNA damage and UV sensitivity. Cell Cycle. 8:655–664. 2009. View Article : Google Scholar : PubMed/NCBI
11	Paulino AC and Okcu MF: Rhabdomyosarcoma. Curr Probl Cancer. 32:7–34. 2008. View Article : Google Scholar : PubMed/NCBI
12	Sivasubramaniam S, Sun X, Pan YR, Wang S and Lee EY: Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1. Genes Dev. 22:587–600. 2008. View Article : Google Scholar : PubMed/NCBI
13	Yang S, Gao Y, Zhao H and Cao D: Cardiac embryonal rhabdomyosarcoma in an adult. Eur J Cardiothorac Surg. 45:e2332014. View Article : Google Scholar : PubMed/NCBI
14	Raphael S, Yusuf I and Imam I: Childhood rhabdomyosarcoma in Kano, Nigeria: A retrospective analysis of 52 cases. Niger J Med. 24:32–36. 2015.PubMed/NCBI
15	Nigg EA, Čajánek L and Arquint C: The centrosome duplication cycle in health and disease. FEBS Lett. 588:2366–2372. 2014. View Article : Google Scholar : PubMed/NCBI
16	Slaats GG, Ghosh AK, Falke LL, Le Corre S, Shaltiel IA, van de Hoek G, Klasson TD, Stokman MF, Logister I, Verhaar MC, et al: Nephronophthisis-associated CEP164 regulates cell cycle progression, apoptosis and epithelial-to-mesenchymal transition. PLoS Genet. 10:e10045942014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Inhibition of centrosomal protein 164 sensitizes rhabdomyosarcoma cells to radiotherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles